Quarterly report pursuant to Section 13 or 15(d)

Acquisition of Patents and Intangibles - Balances, impairment (Details)

v3.21.1
Acquisition of Patents and Intangibles - Balances, impairment (Details) - USD ($)
$ in Thousands, shares in Millions
3 Months Ended 9 Months Ended
Mar. 19, 2021
Feb. 28, 2021
Feb. 28, 2021
May 31, 2020
Feb. 29, 2020
Acquired Finite-Lived Intangible Assets [Line Items]          
Finite-Lived Intangible Assets, Gross   $ 6,446 $ 6,446 $ 18,646  
Accumulated amortization, net of impairment   (4,531) (4,531) (5,190)  
Total amortizable intangible assets, net   1,915 1,915 13,456  
Patents currently not amortized   0 0 0  
Carrying value of intangibles, net   1,915 1,915 13,456  
Intangible asset impairment charge   10,049 10,049    
Impairment charge, gross   12,200      
Impairment charge, reversal of accumulated amortization   2,200      
Subsequent Event          
Acquired Finite-Lived Intangible Assets [Line Items]          
Shares subject to arbitration 3.1        
Patents          
Acquired Finite-Lived Intangible Assets [Line Items]          
Finite-Lived Intangible Assets, Gross   3,500 3,500 3,500 $ 3,500
Intangible Assets Obtained From ProstaGene L L C [Member]          
Acquired Finite-Lived Intangible Assets [Line Items]          
Finite-Lived Intangible Assets, Gross   2,926 2,926 15,126  
Website development costs          
Acquired Finite-Lived Intangible Assets [Line Items]          
Finite-Lived Intangible Assets, Gross   $ 20 $ 20 $ 20